Using MRI to assess growth patterns in liver metastases from colorectal cancer
Official title: Noninvasive Evaluation in Diagnosis and Treatment of Histopathological Growth Patterns in Colorectal Liver Metastases Using MR Elastography-based Shear Strain Mapping
Run by Shengjing Hospital · NCT06208397 · Data updated 2026-11-12
This study is testing if a special type of MRI can help doctors see how colorectal cancer spreads in the liver to improve treatment plans for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Shengjing Hospital Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | December 24, 2023 |
| Main results expected | December 24, 2025 |
| Study ends | December 24, 2026 |
| Registry record updated | May 15, 2025 |
| Trial ID | NCT06208397 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with colorectal liver metastases who have undergone surgical pathology evaluation.
✕Probably not a fit
Patients with CRLM smaller than 1 cm or those with significant organ dysfunction or other malignancies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of Magnetic Resonance Elastography (MRE) in noninvasively detecting histopathological growth patterns (HGP) in patients with colorectal liver metastases (CRLM). By measuring tumor-liver adhesion, the study seeks to correlate imaging findings with pathophysiological changes in the liver. Given the high incidence and mortality rates associated with colorectal cancer, understanding HGP could significantly influence preoperative treatment planning and improve patient outcomes. The study will include patients with confirmed CRLM who meet specific eligibility criteria.
Why it matters
Potential benefit: If successful, this study could enhance preoperative treatment planning for patients with colorectal liver metastases, potentially improving survival rates.
How similar studies have gone: While there have been efforts to identify histopathological growth patterns through imaging, this specific approach using MRE is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed CRLM * Pathologic results obtained in surgical patients * No contraindications for magnetic resonance imaging examination Exclusion Criteria: * Image quality does not meet the measurement requirements. * the diameter of CRLM \<1cm * Combined with other important organ dysfunction * Combined with malignant tumor * Patients who do not sign an informed consent * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)
Where it's running
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China Recruiting
Study contacts
- Principal investigator: Yu Shi, M.D. — Shengjing Hospital
- Study coordinator: Yu Shi, M.D.
- Email: 18940259980@163.com
- Phone: 18940259980
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer
This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Immunotherapy plus Simvastatin and Targeted Therapy with Chemotherapy for Advanced Colorectal Cancer
This trial tests whether adding immune therapy (adbelimumab? actually Adebrelimab) with simvastatin and targeted therapy to standard chemotherapy helps people with metastatic colorectal cancer that is MSI-H/dMMR or MSS/pMMR depending on combination.
-
Fruquintinib treatment in adults with metastatic colorectal cancer in Poland
This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.
-
Understanding why BRAF V600E colorectal cancer stops responding to targeted therapy
This study tests why metastatic colorectal cancer with a BRAF V600E mutation stops responding to encorafenib and cetuximab, by collecting tissue, blood, and stool samples over time.
-
Second-line combination treatment for MSS metastatic colorectal cancer
This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.